Last reviewed · How we verify
AiDing Diuresis wIth Tolvaptan (ADD-IT)
The purpose of this study is to test the use of tolvaptan (commercial name Samsca) when given in addition to intravenous (IV) diuretics early during an episode of acute heart failure. It will be compared to a high dose of IV diuretics alone or the use of metolazone in addition to IV diuretics. The investigators are looking to see if there is improvement in the symptoms and outcomes of persons with acute heart failure.
Details
| Lead sponsor | Emory University |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 14 |
| Start date | 2016-01 |
| Completion | 2018-12-30 |
Conditions
- Cardiomyopathy
- Congestive Heart Failure
Interventions
- Tolvaptan 30 mg + IV Diuretics
- Metolazone 5 mg + IV Diuretics
- 2.5 times the Diuretics Dose
Primary outcomes
- Length of Hospitalization Measured in Days — Duration of Hospitalization (Average of Five Days)
The number of days hospitalized until discharge.
Countries
United States